NCT03426761View on ClinicalTrials.gov

Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Bone InfectionOsteomyelitisSeptic ArthritisJoint InfectionProsthetic Joint Infection
Interventions
DRUG

Dalbavancin

Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions

DRUG

Vancomycin

Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks

Trial Locations (1)

22003

Infectious Diseases Physicians, Inc., Annandale

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

Infectious Diseases Physicians, Inc.

OTHER

NCT03426761 - Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections | Biotech Hunter | Biotech Hunter